BioCentury
ARTICLE | Company News

Cylene Pharmaceuticals, Horizon Discovery Ltd. deal

October 25, 2010 7:00 AM UTC

Cylene will use Horizon's X-MAN panel of over 250 genetically-defined human cancer cell lines to identify patients who will respond best to Cylene's oral protein kinase CK2 inhibitor, CX-4945, in an...